Kathryn Kolibaba, MD | Authors


A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma

December 06, 2016

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma

January 06, 2016

Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.